Astria Therapeutics, Inc.
ATXS evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $718.1M
- Lead Asset:
- navenibart (formerly STAR-0215) (Phase 3)
What it means
What to watch
Prepared research question
What matters most for ATXS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 3 pipeline candidates · 5 clinical trials for Astria Therapeutics, Inc..
Run Astria Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Astria Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Astria Therapeutics, Inc.'s lead drug candidate?
Astria Therapeutics, Inc.'s most advanced tracked candidate is navenibart (formerly STAR-0215) (Phase 3) for Healthy Participants.
Who is the CEO of Astria Therapeutics, Inc.?
Chief Executive Officer is the chief executive officer of Astria Therapeutics, Inc. (ATXS).
Where is Astria Therapeutics, Inc. headquartered?
Astria Therapeutics, Inc. (ATXS) is headquartered in Boston, MA, United States.
What therapeutic areas does Astria Therapeutics, Inc. focus on?
Astria Therapeutics, Inc. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.